Kazia Therapeutics Ltd: Form 20-F for the period ended Jun 30, 2019
Filed with the SEC on Oct 21, 2019 and accepted by EDGAR at Oct 21, 2019, 08:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Income tax | 12 months2018-07-01 to 2019-06-30 | −AUD 298.0k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2018-07-01 to 2019-06-30 | −AUD 10.3m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2018-07-01 to 2019-06-30 | −AUD 17.86 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2018-07-01 to 2019-06-30 | −AUD 17.86 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2018-07-01 to 2019-06-30 | −AUD 6.7m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2019-06-30 | AUD 5.4m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2019-06-30 | AUD 7.5m | ifrs-full:CurrentAssets |
| Total assets | At period end2019-06-30 | AUD 21.2m | ifrs-full:Assets |
| Current liabilities | At period end2019-06-30 | AUD 1.9m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2019-06-30 | AUD 7.0m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2019-06-30 | AUD 14.2m | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2019-06-30 | 62,166,673 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001193125-19-270437. Last ingested by Listed: Nov 2, 2026, 16:21 ET. Listed shows no prices and gives no investment advice.